Testing for SOX10 has been found to be a sensitive and specific marker of melanoma. SOX10 has also been found to be expressed in all melanoma subtypes and therefore is useful in diagnosing a wide range of melanomas [1] [2].
S100B was found to be a highly sensitive test for melanoma and there is accumulating evidence that it can also be used as an early biomarker for the return of a tumor [2] [3]. Also to be considered, testing for S100B has a low specificity due to the fact that it can be expressed in other tumor types [2].
Thanks for adding your suggestions here. Watch that your citations go after the punctuation (no spaces) like this.1 I have adjusted a few dates on your references. This is not something that you did wrong, just a small glitch with the PMID/DOI tool. JenOttawa ( talk) 20:34, 5 November 2018 (UTC)
- ^ Mohamed, Amr; Gonzalez, Raul S.; Lawson, Diane; Wang, Jason; Cohen, Cynthia (2013). "SOX10 expression in malignant melanoma, carcinoma, and normal tissues". Applied immunohistochemistry & molecular morphology: AIMM. 21 (6): 506–510. doi: 10.1097/PAI.0b013e318279bc0a. ISSN 1533-4058. PMID 23197006.
- ^ a b c "Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update". Human Pathology. 45 (2): 191–205. 2014-02-01. doi: 10.1016/j.humpath.2013.02.007. ISSN 0046-8177.
- ^ Bouwhuis, M.G.; Suciu, S.; Kruit, W.; Salès, F.; Stoitchkov, K.; Patel, P.; Cocquyt, V.; Thomas, J.; Liénard, D. (2011). "Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952". European Journal of Cancer. 47 (3): 361–368. doi: 10.1016/j.ejca.2010.10.005. ISSN 0959-8049.
Testing for SOX10 has been found to be a sensitive and specific marker of melanoma. SOX10 has also been found to be expressed in all melanoma subtypes and therefore is useful in diagnosing a wide range of melanomas [1] [2].
S100B was found to be a highly sensitive test for melanoma and there is accumulating evidence that it can also be used as an early biomarker for the return of a tumor [2] [3]. Also to be considered, testing for S100B has a low specificity due to the fact that it can be expressed in other tumor types [2].
Thanks for adding your suggestions here. Watch that your citations go after the punctuation (no spaces) like this.1 I have adjusted a few dates on your references. This is not something that you did wrong, just a small glitch with the PMID/DOI tool. JenOttawa ( talk) 20:34, 5 November 2018 (UTC)
- ^ Mohamed, Amr; Gonzalez, Raul S.; Lawson, Diane; Wang, Jason; Cohen, Cynthia (2013). "SOX10 expression in malignant melanoma, carcinoma, and normal tissues". Applied immunohistochemistry & molecular morphology: AIMM. 21 (6): 506–510. doi: 10.1097/PAI.0b013e318279bc0a. ISSN 1533-4058. PMID 23197006.
- ^ a b c "Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update". Human Pathology. 45 (2): 191–205. 2014-02-01. doi: 10.1016/j.humpath.2013.02.007. ISSN 0046-8177.
- ^ Bouwhuis, M.G.; Suciu, S.; Kruit, W.; Salès, F.; Stoitchkov, K.; Patel, P.; Cocquyt, V.; Thomas, J.; Liénard, D. (2011). "Prognostic value of serial blood S100B determinations in stage IIB–III melanoma patients: A corollary study to EORTC trial 18952". European Journal of Cancer. 47 (3): 361–368. doi: 10.1016/j.ejca.2010.10.005. ISSN 0959-8049.